Climb Bio Inc. (NASDAQ:CLYM) is one of the best stocks under $3 to invest in. On October 16, William Blair analyst Matt Phipps initiated coverage of Climb Bio with an Outperform rating but no price target. The positive rating is based on the potential of the company’s CD19 antibody, budoprutug, which is currently being developed for various autoimmune indications. William Blair Initiates Coverage of Climb Bio (CLYM) with Outperform Rating on Autoimmune Drug Potential Earlier on October 13, H.C. Wainwrigh ...